A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

NCT05341557 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Lymphoma
NSCLC
HCC

Interventions

DRUG: BPI-371153

Sponsor

Betta Pharmaceuticals Co., Ltd.